Reconstruction of T cell infiltration in an osteosarcoma PDX-organoid interactive biobank for personalized immunotherapy.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 41763214.
- Also identified by DOI 10.1016/j.xcrm.2026.102644 and PMC identifier 13006418.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Osteosarcoma (OS) is an aggressive malignant bone tumor with limited therapeutic options and low response to immunotherapy. OS rarity slows clinical translation, highlighting the need for models that bridge patient-derived xenograft (PDX) systems and next-generation platforms. Here, we establish an OS PDX-organoid interactive biobank by self-assembling single-cell suspensions into individualized OS organoids (iOSs). iOS models recapitulate OS spatial and architectural features at millimeter scale in vitro and as xenografts and maintain functional pairing with matched PDX models. We validate iOS fidelity using histopathology, spatial features, genomics, transcriptomics, and pharmacogenomics. By reconstructing T cell infiltration in PDX-derived iOS models, we model treatment-associated immune responses and support immunotherapy translational studies. Using paired iOS-PDX models, we show that a PRMT5<sup>MTA</sup> inhibitor enhances immunotherapy response in chromosome 9p21.3-deleted OS.
Medical subject headings
- Osteosarcoma
- Immunotherapy
- T-Lymphocytes
- Precision Medicine
- Organoids
- Bone Neoplasms
- Lymphocytes, Tumor-Infiltrating